💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ticagrelor

CHEMBL398435 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
522.6 g/mol
LogP
2.0
Phase
4

This antiplatelet medication is used to prevent blood clots in people who have had a heart attack or unstable angina, reducing the risk of future heart attacks and strokes. It works by blocking a receptor on platelets called P2Y12, making platelets less likely to clump together. It is typically taken along with low-dose aspirin and should not be stopped without consulting a doctor.

आणविक भार

522.6000 g/mol

LogP

2.00

TPSA

164.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

चिकित्सीय क्षेत्र

अनिद्रा एट्रियल फ़िब्रिलेशन क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) क्रॉनिक किडनी डिज़ीज़ गाउट (गठिया) टाइप 2 मधुमेह डीप वेन थ्रोम्बोसिस / पल्मोनरी एम्बोलिज़्म माइग्रेन रुमेटॉइड आर्थराइटिस सिस्टेमिक ल्यूपस एरिथेमेटोसस स्ट्रोक हृदय विफलता हृदय-संवहनी रोग

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1

                

                

                
                

                    
InChI

                    
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H28F2N6O4S

                    

                    
                    

                        
HBD / HBA

                        
4 / 12

                    

                    
                    

                        
घूर्णनीय बंधन

                        
10

                    

                    
                    
                    

                        
भारी परमाणु

                        
36

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
This antiplatelet medication is used to prevent blood clots in people who have had a heart attack or unstable angina, reducing the risk of future heart attacks and strokes. It works by blocking a receptor on platelets called P2Y12, making platelets less likely to clump together. It is typically taken along with low-dose aspirin and should not be stopped without consulting a doctor.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Ticagrelor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL398435.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9871419.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.